Health News

MUMBAI, India & BASEL, Switzerland--(BUSINESS WIRE)--SynSmart and Amporin today announced a collaboration to develop breakthrough small molecule therapeutics for degenerative diseases....

AHLEN, Germany--(BUSINESS WIRE)--A natural and healthy appearance is considered the number one beauty ideal. This is based on a balanced diet and an adequate supply of essential nutrients. However, the body cannot always sufficiently produce or absorb all important nutrients itself. This is exactly where LR Health & Beauty comes in with the LR 5in1 Beauty Elixir and the LR 5in1 Men's Shot. Both products have now been further developed in terms of formulation and design. With this optimizati...

IRVINE, Calif.--(BUSINESS WIRE)--SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced the pricing of the underwritten secondary public offering of 3,100,000 shares of the Company’s common stock by Dr. Yoshiyuki Aikawa (the “Selling Stockholder”) at the public offering price of $3.25 per share. Additionally, the Selling Stockholder has granted the unde...

SAN CARLOS, Calif.--(BUSINESS WIRE)--Synthetic Design Lab unveils first advanced logic-gated ADC at AACR 2026, achieving ≥10X improvement in targeted cancer cell killing...

SAN MATEO, Calif.--(BUSINESS WIRE)--EpiBiologics, a leader in tissue-selective extracellular protein degradation, today announced that the first patient has been dosed with EPI-326 in its global Phase 1 clinical study. EPI-326 is the company’s tissue-selective bispecific antibody that degrades all oncogenic mutant and wild type forms of EGFR for EGFR-driven cancers. The first-in-human study is evaluating EPI-326 in patients with advanced non-small cell lung cancer (NSCLC) and head and neck squa...

DEERFIELD, Ill.--(BUSINESS WIRE)--Lundbeck presents new data at AAN 2026 highlighting real-world changes in migraine-related cognitive symptoms after starting VYEPTI...

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapies targeting the underlying causes of psychiatric and neurological disorders, today issued the following statement supporting the newly signed White House Executive Order aimed at accelerating research, development, and responsible access to innovative treatments for serious mental illness, including emerging psychedelic medi...

PHOENIX--(BUSINESS WIRE)--At this year’s American Society of Regional Anesthesia and Pain Medicine (ASRA) annual meeting, researchers at Hospital for Special Surgery (HSS) presented two studies focused on glucagon-like peptide-1 (GLP-1) agonist usage in patients undergoing surgery. GLP-1 agonists are a class of medications commonly prescribed to treat type 2 diabetes and obesity, and their therapeutic potential is extending to a range of conditions including cardiovascular and neurodegenerative...

SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Researchers from Inocras, a bioinformatics-led company harnessing the power of whole-genome data and proprietary analytics to advance precision health, and the Broad Institute of MIT and Harvard will jointly present new insights from a collaborative initiative to analyze large-scale whole genome data during the AACR Annual Meeting 2026 in San Diego. The collaboration delivers one of the largest cancer whole-genome analyses from over 8,000 cancer wh...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could h...